Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Study challenges age cutoff for detecting ATTR-CM

  A small but important number of people develop ATTR-CM before age 65 and often have early symptoms that are not limited to the heart.

• Intellia halts ATTR-CM gene editing trials after liver toxicity case

  Intellia Therapeutics paused two phase 3 trials of its CRISPR-based therapy after a patient developed severe liver toxicity.

• Dominican heritage may raise risk of hereditary ATTR-CM variant

  A genetic variant linked to ATTR-CM was more common in Hispanic individuals with more African ancestry, especially Dominican descent.

• Pairing GLP-1 receptor agonists with SGLT2 inhibitors lowers risk of death in ATTR-CM

  Patients with ATTR-CM who took both GLP-1RA and SGLT2i had lower death rates and fewer heart events than those on SGLT2i alone.

• ATTR-CM may contribute to death in patients with Alzheimer’s disease

  Cardiac transthyretin amyloidosis (ATTR-CM) was found in 12% of patients with Alzheimer’s disease and heart enlargement after death.

• Exercise training improves function and quality of life in heart failure

  Tailored exercise programs can reduce symptoms and improve quality of life in patients with HFpEF, including those with ATTR-CM.

• Survey insights emphasize need to improve life with amyloidosis

  Patients with amyloidosis, including ATTR-CM, value longevity, affordability and symptom relief above all.

• New study urges broader screening for underrecognized ATTR-CM

  One-third of patients diagnosed with ATTR-CM had normal heart wall thickness, suggesting current screening may miss early-stage cases.

• RNAi therapies show promise for heart complications in ATTR-CM

  RNAi therapies may reduce heart-related complications in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

• New review explores benefits from recent advances in ATTR-CM treatment options

  Tafamidis and acoramidis reduce mortality and improve quality of life for many patients living with ATTR-CM.